Rhizen Pharmaceuticals S.A. Announces Preclinical Presentations On RP6530, A Dual PI3K Delta/Gamma Inhibitor, For The Treatment Of Hematological Malignancies At The 55th Annual Meeting Of The American Society of Hematology, 2013
11/19/2013 9:12:43 AM
La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for its clinical lead, RP6530, a novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, in B & T-cell Lymphomas, at the Annual meeting of the American Society of Hematology (ASH) 2013 to be held from December 07-10, at New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by